Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-1968 in anal HSIL
NCT03677960Phase 1Terminated
- Sponsor
- Antiva Biosciences
- Start
- Dec 2018
- Primary completion
- Jun 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of abi-1968 in anal squamous intraepithelial lesion (ASIL) (3 arms), sponsored by Antiva Biosciences. Primary endpoint: Maximum Tolerated Dose at 84 days. Started Dec 2018; status: terminated.
02
Drugs
abi-1968
03
Conditions
anal squamous intraepithelial lesion (ASIL)
Beyond the preview
Go deeper on NCT03677960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03677960.